JAPANESE TRADE AGREEMENT COULD BOOST U.S. MEDICAL SALES TO JAPAN BY $500 MIL.
This article was originally published in The Gray Sheet
Executive Summary
JAPANESE TRADE AGREEMENT COULD BOOST U.S. MEDICAL SALES TO JAPAN BY $500 MIL. per year three years after the agreement takes effect on Nov. 1, the Health Industry Manufacturers Association estimates. HIMA, which served as an advisor to the U.S. trade team during the negotiations, predicts that under the trade accord, U.S. sales to government-managed hospitals, research facilities and critical care centers in Japan will increase from current levels of $700 mil. per year, to nearly $1 bil. after three years, while annual sales to Japan's private medical sector are expected to increase $200 mil.
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.